95,050 total recalls in our database
Harmless Harvest
Firm is voluntarily recalling specific lots of Harmless Harvests Dairy-Free Yogurt Drink beverages after identifying a possible packaging defect that may result in premature spoilage
Firm is voluntarily recalling specific lots of Harmless Harvest s Dairy-Free Yogurt Drink beverages after identifying a possible packaging defect that may result in premature spoilage
Microbial contamination with Bacillius circulans and Bacillus cereus / thuringiensis / mycoides.
Formed Potato Tater Puffs (H30 s), sold as a foodservice item, are recalled due to contamination with plastic object.
WAWA has initiated a recall of Wawa Iced Tea Less Sugar, Net weight/number of units per package: 12 FL OZ. , Package type: Bottle Units per case: 24, Expiration date: April 29, 2019 (APR/29/19) because of mislabeling. The label reads does not list required phenylketonuria warning and ingredient listing does not list Aspartame.
Scallop flavor used in the product contains low levels of crustaceans (1 ppm) that is not listed on the product label.
Caesar's Pasta
A sub-ingredient of the product may be contaminated with Listeria monocytogenes or Salmonella.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Customceutical Compounding
Lack of assurance of sterility for injectables and solutions intended to be sterile.
American Health Packaging
Failed Dissolution Specifications: dissolution failure at time zero of the repackaged lot. Drug release results were slightly above specification at time zero.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.
Customceutical Compounding
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Customceutical Compounding
Lack of assurance of sterility for injectables and solutions intended to be sterile.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.
Customceutical Compounding
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Customceutical Compounding
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Lack of assurance of sterility for injectables and solutions intended to be sterile.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 0.96 parts per million.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.